Trial Profile
Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom in Ocular Hypertensive or Glaucomatous Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2020
Price :
$35
*
At a glance
- Drugs Latanoprost/timolol (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Laboratoires Thea
- 04 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2014 New trial record